Status: Recruiting
SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure
To investigate the efficacy of SHR-1701 combined with Rivoceranib, with or without SHR-2554, in patients with gastric or gastroesophageal junction adenocarcinoma who have progressed on or were intolerant to first-line immunotherapy-containing treatment
Participants needed: 40
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Jingdong ZhangUpdated: Dec 31, 2025Locations: 1
Eligibility criteria
Age ≥ 18 years, male or female. [+18]
Gastrointestinal perforation and/or fistula within 6 months prior to treatment,... [+18]